rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Michael Landsittel

Director

Company insider

Files Form 4 as: Director, Damora Therapeutics; Chief Financial Officer, Blueprint Medicines.

Every Form 4 they filed

In numbers

Trades disclosed
61
Buys
0
Sells
12
Bought
$0
Sold
$4.9M
Companies
2
Companies where not an officer
1
First trade
3 Feb 2016
Last trade
23 Mar 2026
Last filed
25 Mar 2026

Companies traded

Where they are an officer
Blueprint MedicinesOfficer · last 17 Jul 20250 buys · 12 sells
Everywhere else they filed: board seats, 10% stakes, other companies
DMRA Damora TherapeuticsDirector · Biotechnology · last 23 Mar 20260 buys · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
10Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
23 Mar 2026filed 25 Mar 2026DMRA Damora Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—37,313 at $0.00filing
23 Mar 2026filed 25 Mar 2026DMRA Damora Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—37,313 at $0.00filing
17 Jul 2025filed 21 Jul 2025Blueprint Medicinesoption or derivativeSEC FORM 4 Code D—10,000filing
17 Jul 2025filed 21 Jul 2025Blueprint Medicinesoption or derivativeSEC FORM 4 Code D—26,000filing
17 Jul 2025filed 21 Jul 2025Blueprint Medicinesoption or derivativeSEC FORM 4 Code D—19,500filing
17 Jul 2025filed 21 Jul 2025Blueprint Medicinesoption or derivativeSEC FORM 4 Code D—25,000filing
17 Jul 2025filed 21 Jul 2025Blueprint Medicinesoption or derivativeSEC FORM 4 Code D—26,125filing
17 Jul 2025filed 21 Jul 2025Blueprint Medicinesoption or derivativeSEC FORM 4 Code D—25,000filing
17 Jul 2025filed 21 Jul 2025Blueprint Medicinesoption or derivativeSEC FORM 4 Code D—25,000filing
17 Jul 2025filed 21 Jul 2025Blueprint Medicinesoption or derivativeSEC FORM 4 Code D—25,000filing
17 Jul 2025filed 21 Jul 2025Blueprint Medicinesoption or derivativeSEC FORM 4 Code D—22,000filing
17 Jul 2025filed 21 Jul 2025Blueprint MedicinesSEC FORM 4 Code A—21,353filing
17 Jul 2025filed 21 Jul 2025Blueprint MedicinesSEC FORM 4 Code D—51,102filing
17 Jul 2025filed 21 Jul 2025Blueprint MedicinesSEC FORM 4 Code U—43,175filing
5 Mar 2025filed 7 Mar 2025Blueprint MedicinesSEC FORM 4 Sold$469K5,284 at $88.80filing
1 Mar 2025filed 4 Mar 2025Blueprint Medicinesoption or derivativeSEC FORM 4 Code A—22,000 at $0.00filing
1 Mar 2025filed 4 Mar 2025Blueprint MedicinesSEC FORM 4 Code A—11,000 at $0.00filing
15 Aug 2024filed 19 Aug 2024Blueprint MedicinesSEC FORM 4 Sold$420K4,409 at $95.23filing
15 May 2024filed 17 May 2024Blueprint MedicinesSEC FORM 4 Sold$266K2,486 at $107.17filing
15 May 2024filed 17 May 2024Blueprint MedicinesSEC FORM 4 Sold$145K1,364 at $106.56filing

News

Remix Therapeutics™ Appoints Michael Landsittel to Board of Directorsmanilatimes.net · 6 Oct 2026

1 headline in the last 90 days name Michael Landsittel; no company of theirs resolves to a name we track.

Sectors

Not placed12

Buys in green, sells in red, by the company’s sector.

Related people

Nobody else traded the same names lately.